Previous 10 | Next 10 |
Sera Prognostics press release ( NASDAQ: SERA ): Q3 GAAP EPS of -$0.35. Revenue of $87,000 compared to $23,000 for the same period of 2021. Total operating expenses were $11.3 million, up from $9.5 million for the third quarter of 2021. For further detail...
SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS PR Newswire SALT LAKE CITY , Nov. 9, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by pro...
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9 PR Newswire SALT LAKE CITY , Oct. 27, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), ...
SONRAVA HEALTH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH CEREBRAE AND SERA PROGNOSTICS PR Newswire The value created by applying Sera's PreTRM® test and treat strategy ...
BANNER HEALTH, SERA PROGNOSTICS TEAM UP TO PROVIDE PreTRM® TEST TO COVERED PREGNANT MEMBERS PR Newswire First and only broadly clinically validated test to provide accurate and actionable information to help reduce the morbidity, mortality, and costs associate...
Image source: The Motley Fool. Sera Prognostics, Inc. (NASDAQ: SERA) Q2 2022 Earnings Call Aug 10, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Sera Prognostics, Inc. (SERA) Q2 2022 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) Q2 2022 Earnings Conference Call August 10, 2022 05:00 PM ET Company Participants Peter DeNardo - CapComm Partners Greg Critchfield - Chairman, President & Chief Executive Officer Jay Moyes - Chief Financial Officer Confere...
Sera Prognostics press release ( NASDAQ: SERA ): Q2 GAAP EPS of -$0.37 beats by $0.03 . Revenue of $0.07M (+250.0% Y/Y) misses by $0.02M . For further details see: Sera Prognostics GAAP EPS of -$0.37 beats by $0.03, revenue of $0.07M misses by $0.02M
SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS PR Newswire SALT LAKE CITY , Aug. 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing inn...
SERA sells PreTRM®, a CLIA-lab based assay to determine the risk of a woman having a pre-term birth – a birth prior to 37 weeks of gestation. After IPO'ing in July 2021 at $16, the Company has since lost over 80% of its value and trades at 50% of its cash and marketable se...
News, Short Squeeze, Breakout and More Instantly...
Sera Prognostics Inc. Company Name:
SERA Stock Symbol:
NASDAQ Market:
Sera Prognostics Inc. Website:
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024 PR Newswire SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA)...
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial PR Newswire Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-R...
2024-07-06 13:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...